Literature DB >> 16546039

Thyroid transcription factor-1 staining is useful in identifying brain metastases of pulmonary origin.

Alan L Prok1, Richard A Prayson.   

Abstract

Metastatic carcinomas of the brain are a common intracranial tumor and may be the first manifestation of the cancer in a patient. The primary site of these tumors is often difficult to determine based solely on histology. Thyroid transcription factor-1 (TTF-1) is a fairly specific immunohistochemical marker for primary lung and thyroid carcinomas. Recent studies have indicated that TTF-1 may be useful in identifying metastatic brain carcinomas arising from primary lung carcinomas. This study evaluates TTF-1 immunoreactivity in 101 metastatic brain carcinomas and 50 glioblastoma multiform. In patients with a known pulmonary primary, 59% of the metastases were positive for TTF-1. The one patient with a thyroid primary also had a metastasis positive for TTF-1. None of the metastatic lesions arising from other sites was positive for TTF-1. None of the 50 glioblastoma multiform was positive for TTF-1. This study indicates that TTF-1 may be useful in evaluating metastatic carcinomas of unknown primary and TTF-1 immunoreactivity may be indicative of a lung or thyroid primary.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16546039     DOI: 10.1016/j.anndiagpath.2005.07.013

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  3 in total

Review 1.  Review: the role of neural crest cells in the endocrine system.

Authors:  Meghan Sara Adams; Marianne Bronner-Fraser
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

2.  TTF-1 staining in glioblastoma multiforme.

Authors:  Malcolm Galloway; Rosalind Sim
Journal:  Virchows Arch       Date:  2007-06-12       Impact factor: 4.064

3.  Extrapulmonary small cell carcinoma: involvement of the brain without evidence of extracranial malignancy by serial PET/CT scans.

Authors:  Christopher N Hueser; Nghi C Nguyen; Medhat Osman; Necat Havlioglu; Anjali J Patel
Journal:  World J Surg Oncol       Date:  2008-09-25       Impact factor: 2.754

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.